Last updated: February 20, 2026
What is the drug with NDC 68382-0330?
NDC 68382-0330 corresponds to Eptinezumab. It is marketed under the brand name Vyepti by Lundbeck and is approved for the preventive treatment of migraine in adults. Eptinezumab is a monoclonal antibody targeting calcitonin gene-related peptide (CGRP).
Market size and competitive landscape
The demand for migraine preventive therapies has increased due to rising awareness and diagnostic rates. Eptinezumab entered the market alongside other CGRP inhibitors:
| Drug Name |
Approval Date |
Administration |
Annual Cost (US) |
Market Position |
| Eptinezumab (Vyepti) |
February 2020 |
Intravenous |
~$6,500 per dose |
Recent entrant, targeting infrequent dosing |
| Fremanezumab (Ajovy) |
June 2018 |
Subcutaneous |
~$6,000 per year |
Competition, established in market |
| Galcanezumab (Emgality) |
September 2018 |
Subcutaneous |
~$6,500 per year |
Leading CGRP antibody in market |
| Erenumab (Aimovig) |
May 2018 |
Subcutaneous |
~$6,800 per year |
First FDA-approved CGRP inhibitor |
The global migraine therapeutics market was valued at approximately USD 2.6 billion in 2021, with projections to reach USD 4 billion by 2028, growing at a CAGR of about 8%. The CGRP inhibitor segment dominates due to efficacy and convenience.
Pricing analysis
Eptinezumab's higher price point is justified by its intravenous administration, which reduces dosing frequency:
- Per-dose cost: Approximately USD 6,500.
- Annual cost (assuming quarterly dosing): ~$26,000.
- vs. subcutaneous options: ~$6,000–$6,800 annually.
The higher cost reflects the manufacturing complexity and intravenous delivery but is offset by less frequent administration (quarterly or bi-quarterly) compared to weekly or monthly subcutaneous options.
Revenue projections
Based on market uptake estimates and pricing:
| Year |
Estimated Units Sold |
Revenue (USD millions) |
Assumptions |
| 2023 |
15,000 patients |
~$97.5 |
Moderate uptake, driven by neurologist adoption |
| 2024 |
25,000 patients |
~$162.5 |
Increased awareness, formulary inclusion |
| 2025 |
40,000 patients |
~$260 |
Expanded coverage, new indications |
Market penetration relies on formulary access, physician preference, and patient acceptance of IV therapy. The total addressable patient pool is approximately 40-50% of migraine sufferers, estimated at 39 million globally.
Regulatory and reimbursement considerations
- Medicare and private insurers often favor subcutaneous treatments due to convenience.
- Reimbursement codes assigned in 2020 (CPT codes 96401-96405 for infusion) facilitate administration and billing.
- Payers may negotiate discounts, influencing net pricing and profit margins.
Key drivers and risks
Drivers
- Increasing migraine prevalence
- Patient preference for less frequent infusions
- Efficacy demonstrated in clinical trials
- Growing awareness and diagnosis
Risks
- Competition from emerging therapies
- Reimbursement challenges
- Price sensitivity in payers
- Manufacturing complexities and costs
Summary
Eptinezumab (NDC 68382-0330) has a niche positioned around infusion-based quarterly dosing. Its market share will depend on ongoing clinical data, payer acceptance, and competitive dynamics. Price projections suggest steady growth, with revenue potential reaching hundreds of millions USD annually in key markets through 2025.
Key Takeaways
- The drug's high price reflects IV administration and clinical benefits.
- Market growth is driven by increasing migraine prevalence and awareness.
- Competition from subcutaneous CGRP inhibitors influences market share.
- Reimbursement policies will significantly impact revenue realization.
- Financial success hinges on expanding payer acceptance and optimizing manufacturing costs.
FAQs
1. How does Eptinezumab's pricing compare to other CGRP inhibitors?
It is approximately 20-25% higher per year due to its intravenous delivery, which requires specialized administration.
2. What is the main competition for Eptinezumab?
Fremanezumab, Galcanezumab, and Erenumab, which are subcutaneously administered, are primary competitors.
3. What factors could affect Eptinezumab's revenue growth?
Payer reimbursement policies, clinical efficacy data, market acceptance, and competition.
4. Are there any upcoming regulatory or coverage decisions that could influence pricing?
Potential formulary decisions and updates to reimbursement codes could impact market access and revenue.
5. What is the patient population size for migraine prophylaxis?
Approximately 39 million globally are affected, with an estimated 40-50% candidates for preventive therapy.
References
[1] Grand View Research. (2022). Migraine Therapeutics Market Size, Share & Trends Analysis.
[2] FDA. (2020). Highlights of Prescribing Information.
[3] IQVIA. (2022). Market Data and Forecasts for Migraine Therapeutics.
